About RELIEF THERAPEUTICS Holding AG

Company Description

Relief is a biopharmaceutical company whose objective is to provide patients with therapeutic RELIEF in serious diseases with high unmet medical need.

We focus on clinical-stage programs based on molecules with a history of clinical use (well-established safety and tolerability) and either initial human activity or efficacy data (proof of concept) or a strong scientific rationale. This allows us to identify molecules where clinical development can be swift (trials with evaluation windows of weeks or months) and cost effective. Our lead compound is RLF-100™, a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action, for respiratory indications. The development program currently is focused on COVID-19-induced severe lung injury and pulmonary sarcoidosis. These are two diseases for which an unmet medical need exists. Clinical development opportunities of RLF-100™ for other indications in both acute and chronic lung diseases are being evaluated.

Year founded

2013

Served area

Worldwide

Headquarters

Avenue de Sécheron 15, 1202 Genève – Switzerland

Shareholder information

Shares outstanding

4,413,334,617

IPO

Sept. 19, 2011

Stock exchange(s)

SIX Swiss Exchange

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.